cis-3,4-dihydroxycyclopentanecarboxylic acid | 1106887-87-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羟基酸及其衍生物
• 英文名称: cis-3,4-dihydroxycyclopentanecarboxylic acid
• 英文别名: (1S,3R,4S)-3,4-dihydroxycyclopentane-1-carboxylic acid；(3S,4R)-3,4-dihydroxycyclopentane-1-carboxylic acid
• CAS: 1106887-87-9
• 化学式: C₆H₁₀O₄
• 分子量: 146.143
• InChiKey: NPAXFZBGZWAVIF-NVGWPGHNSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  10
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  77.8
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  2-phenylpropan-2-yl cis-3,4-dihydroxycyclopentanecarboxylate 在 盐酸 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 以98%的产率得到cis-3,4-dihydroxycyclopentanecarboxylic acid
  参考文献：
  名称：

  [EN] PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
  [FR] DÉRIVÉS DE PIPÉRIDINE EN TANT QUE MODULATEURS D'ACTIVITÉ DE RÉCEPTEUR DE CHIMIOKINE

  摘要：

  本申请描述了公式（I）的MIP-1调节剂：或其立体异构体或药用可接受的盐，其中m、Q、T、W、Z、R1、R3、R4、R5、R5a和R5b如上所述。此外，还公开了利用这些调节剂治疗和预防哮喘和过敏性疾病等炎症性疾病，以及类风湿关节炎和动脉粥样硬化等自身免疫病理的方法。

  公开号：

  WO2009015166A1

文献信息

• DIURETICS
  申请人：ALI Amjad

  公开号：US20100029678A1

  公开（公告）日：2010-02-04

  A compound having the structure wherein X is selected from the group consisting of: a bond, —NHCH 2 (CH 2 ) n CH 2 OC(O)—, —CH 2 NHC(O)CH 2 NHC(O)—, —CH 2 OC(O)—, —OCH(CH 3 )OC(O)—, —OCH 2 OC(O)—, —O—, —NR 1 —, —CR 1 R 3 —, —(CH 2 ) p —, —(CH 2 ) q NR 1 C(O)—, —CHR 5 NR 2 C(O)—, —(CH 2 ) q C(O)—, —(CH 2 ) q C(O)—, —(CH 2 ) q C(O)NR 1 —, or a pharmaceutically acceptable salt thereof, and methods of using the compounds for treating, hypertension.

  具有以下结构的化合物： 其中 X 是从以下组中选择： 一个键，—NHCH 2 (CH 2 ) n CH 2 OC(O)—, —CH 2 NHC(O)CH 2 NHC(O)—, —CH 2 OC(O)—, —OCH(CH 3 )OC(O)—, —OCH 2 OC(O)—, —O—, —NR 1 —, —CR 1 R 3 —, —(CH 2 ) p —, —(CH 2 ) q NR 1 C(O)—, —CHR 5 NR 2 C(O)—, —(CH 2 ) q C(O)—, —(CH 2 ) q C(O)—, —(CH 2 ) q C(O)NR 1 —， 或其药物可接受的盐，以及使用这些化合物治疗高血压的方法。
• PIPERIDINE DERIVATIVES AS MODULATORS OF CHEMOKINE RECEPTOR ACTIVITY
  申请人：Santella Joseph B.

  公开号：US20100222366A1

  公开（公告）日：2010-09-02

  The present application describes modulators of MIP-1 of formula (I): or stereoisomers or pharmaceutically acceptable salts thereof, wherein m, Q, T, W, Z, R1, R3, R4, R5, R5a and R5b, are as set forth above. In addition, methods of treating and preventing inflammatory diseases such as asthma and allergic diseases, as well as autoimmune pathologies such as rheumatoid arthritis and atherosclerosis using the modulators are disclosed.

  本申请描述了MIP-1的调节剂，其化学式为(I)：或其立体异构体或药学上可接受的盐，其中m、Q、T、W、Z、R1、R3、R4、R5、R5a和R5b如上所述。此外，还公开了使用这些调节剂治疗和预防炎症性疾病，如哮喘和过敏疾病，以及自身免疫病理，如类风湿性关节炎和动脉粥样硬化的方法。
• NITRO DERIVATIVES OF FURASEMIDE AND THEIR USE AS DIURETICS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2326652B1

  公开（公告）日：2014-04-16
• NITROOXY CYCLOALKANE DERIVATIVES
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP2369924B1

  公开（公告）日：2014-11-26
• DIAZENIUMDIOLATE CYCLOPENTYL DERIVATIVES
  申请人：Ali Amjad

  公开号：US20130053352A1

  公开（公告）日：2013-02-28

  A compound having the structure or a pharmaceutically acceptable salt thereof, wherein R 1 is hydrogen, —OH, —O—C 1-6 alkyl, ═O, or halogen; R 2 is hydrogen, C(O)OR 8 , C 6 H 5 C(O)OR 8 , (CH 2 ) 1-2 OH, CR 9 R 10 OH, C(O)O(CH 2 ) 0-2 aryl, C(O)NR 9 R 10 , C(O)SO 2 NR 9 R 10 , C 6 H 5 OR 9 , W—C(O)OR 8 , W—OR 9 , Y, or P(O)(OR 9 )(ORlO); R 3 is hydrogen or —C 1-6 alkyl; R 4 is hydrogen, —OH or —C(O)OR 9 ; R 5 is hydrogen or deuterium; R 6 and R 7 are independently —C 1-6 alkyl, fluoro-substituted —C 1-6 alkyl, deutero-substituted —C 1-6 alkyl or —(CH 2 ) 1-2 R 11 , wherein any carbon atom of the fluoro-substituted —C 1-6 alkyl is mono- or di-substituted with fluoro, and any carbon atom of the deutero-substituted —C 1-6 alkyl is mono- or di-substituted with fluoro; R 8 , in each instance in which it occurs, is independently hydrogen, —C 1-6 alkyl, or —(CH 2 ) 2 N + (CH 3 ) 3 ; R 9 and R 10 , in each instance in which they occur, are independently —C 1-6 alkyl; R 11 is —OH, —O—C 1-6 alkyl, -0CD3, —OC(O)OC 1-6 alkyl, —NH 2 , —C 6 H 5 , —N 3 , or W; W is an unsubslituted 5- or 6-raembered heteroaryl ring having 1, 2, or 3 nitrogen atoms, or a substituted 5- or 6-membered heteroaryl ring having 1, 2, or 3 nitrogen atoms that is mono- or di-substituted at any carbon atom with R 6 or R 7 ; Y is a 5- or 6-membered heterocyclic ring having 1, 2, 3 or 4 heteroatoms which are N, O, or S or stereoisomers thereof, or pharmaceutically acceptable salts thereof, or pharmaceutically acceptable salts of stereoisomers thereof, and methods of using the compounds for treating hypertension.